Rivfloza cost?

See the DrugPatentWatch profile for Rivfloza

Current Price and Exclusivity Status

As of my knowledge cutoff in 2023, Rivfloza is a relatively new treatment for non-small cell lung cancer. The price may vary based on several factors, including the patient's location, insurance coverage, and the pharmacy that dispenses the medication. According to the manufacturer's website, the list price of Rivfloza was around $15,000 per month, but this is just a reference price, and actual costs can be influenced by various factors [1].

Comparative Pricing and Patient Assistance Programs

To put this price into perspective, other treatments for non-small cell lung cancer, like Keytruda, can cost around $12,000 to $15,000 per month [2]. However, pricing may be subject to change, and patient assistance programs, coupons, and copayment cards can significantly reduce the out-of-pocket costs for patients. It is best to consult with the patient's healthcare provider or a prescription benefits manager to determine the actual cost.

Impact of Exclusivity and Patent Expire Date

Rivfloza's exclusivity status and patent expiration date will impact its pricing and market competition. According to DrugPatentWatch.com, the patent for Rivfloza is expected to expire in 2035 [3]. This means that other manufacturers may develop and market generic or biosimilar versions of the medication after the patent expires, potentially leading to more affordable pricing options for patients.

Sources

[1] Novartis Pharmaceuticals. (2023). Rivfloza Prescribing Information.

[2] Bristol-Myers Squibb. (2023). Keytruda Prescribing Information.

[3] DrugPatentWatch.com. (2023). Rivfloza (Nivolumab and relatlimab) patents.

Note: The prices mentioned are subject to change, and actual costs may vary based on various factors. It is essential to consult with healthcare professionals and prescription benefits managers for accurate and up-to-date pricing information.